For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the emergence of Vyndamax and Tafamidis meglumine represents a genuine breakthrough . These novel therapies stabilize the transthyretin protein, preventing its destructive build-up and lessening the burden of the disease . Patients are now reporting positi